-0.85%
13.93%
22.02%
15.79%
24.30%
9.33%
5.93%
AI Spotlight on HRMY
Company Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States.Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.The company was formerly known as Harmony Biosciences II, Inc.
and changed its name to Harmony Biosciences Holdings, Inc.in February 2020.Harmony Biosciences Holdings, Inc.
was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Market Data
| Last Price | 39.2 |
| Change Percentage | -0.85% |
| Open | 39.7 |
| Previous Close | 39.54 |
| Market Cap ( Millions) | 2236 |
| Volume | 76512 |
| Year High | 41.61 |
| Year Low | 28.14 |
| M A 50 | 34.94 |
| M A 200 | 33.63 |
Financial Ratios
| FCF Yield | 9.85% |
| Dividend Yield | 0.00% |
| ROE | 23.16% |
| Debt / Equity | 30.64% |
| Net Debt / EBIDTA | -100.07% |
| Price To Book | 3.74 |
| Price Earnings Ratio | 18.18 |
| Price To FCF | 10.16 |
| Price To sales | 3.28 |
| EV / EBITDA | 9.94 |
News
- Jan -30 - HRMY vs. RGEN: Which Stock Is the Better Value Option?
- Jan -24 - Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech
- Jan -23 - 4 High Earnings Yield Value Stocks to Buy as Trump Resumes Presidency
- Jan -15 - How Much Upside is Left in Harmony Biosciences (HRMY)? Wall Street Analysts Think 39.48%
- Jan -14 - HRMY or RGEN: Which Is the Better Value Stock Right Now?
- Jan -13 - BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
- Dec -20 - Levi & Korsinsky Announces an Investigation on Behalf of Harmony Biosciences Holdings, Inc. (HRMY) Shareholders Who May Have Been Affected by Fraud
- Dec -19 - Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
- Dec -18 - HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
- Dec -18 - Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
- Dec -17 - Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
- Dec -16 - Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
- Dec -13 - HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
- Dec -12 - Harmony Biosciences Holdings, Inc. Being Investigated on Behalf of Harmony Biosciences Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.
- Dec -11 - Levi & Korsinsky Investigates Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc. (HRMY)
- Dec -10 - Did Harmony Biosciences Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - HRMY
- Dec -09 - Lost Money on Harmony Biosciences Holdings, Inc. (HRMY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
- Dec -06 - Levi & Korsinsky Investigates Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc. (HRMY)
- Dec -05 - Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
- Dec -04 - Harmony Biosciences Holdings, Inc. (HRMY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical
Expected Growth : 8.5 %
What the company do ?
Harmony Biosciences Holdings, Inc. is a pharmaceutical company that develops and commercializes treatments for rare and orphan diseases, focusing on central nervous system disorders.
Why we expect these perspectives ?
Harmony Biosciences Holdings, Inc.'s 8.5% growth in pharmaceuticals is driven by increasing demand for rare disease treatments, strong pipeline of novel therapies, and strategic partnerships. Additionally, growing awareness of sleep disorders and increasing adoption of Wakix, its flagship product, contribute to the segment's growth.
Harmony Biosciences Holdings, Inc. Products
| Product Range | What is it ? |
|---|---|
| Wakix | A medication used to treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy |
| Pitolisant | A medication used to treat excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy |
| Xyrem | A medication used to treat cataplexy and excessive daytime sleepiness in adult patients with narcolepsy |
Harmony Biosciences Holdings, Inc.'s Porter Forces
Threat Of Substitutes
Harmony Biosciences Holdings, Inc. operates in a niche market with limited substitutes, reducing the threat of substitutes.
Bargaining Power Of Customers
Harmony Biosciences Holdings, Inc. has a diverse customer base, reducing the bargaining power of individual customers.
Bargaining Power Of Suppliers
Harmony Biosciences Holdings, Inc. relies on a few key suppliers, giving them some bargaining power, but the company's size and scale mitigate this threat.
Threat Of New Entrants
Harmony Biosciences Holdings, Inc. operates in a highly regulated industry with significant barriers to entry, reducing the threat of new entrants.
Intensity Of Rivalry
Harmony Biosciences Holdings, Inc. operates in a competitive industry with several established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 29.30% |
| Debt Cost | 7.69% |
| Equity Weight | 70.70% |
| Equity Cost | 7.69% |
| WACC | 7.69% |
| Leverage | 41.45% |
Harmony Biosciences Holdings, Inc. : Quality Control
Harmony Biosciences Holdings, Inc. passed 8 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CTMX | CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The … |
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| AKBA | Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral … |
| AMLX | Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax … |
| ITOS | Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Harmony Biosciences
A-Score
1-Year Total Return ->
🥈
Akebia Therapeutics
A-Score
1-Year Total Return ->
🥉
Puma Biotechnology
A-Score
1-Year Total Return ->
4
CytomX Therapeutics
A-Score
1-Year Total Return ->
5
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
6
